MDJobScout :: Medicine :: Surgery :: Cardiothoracic (7)

Permanent Cardiothoracic Surgery Jobs

Cardiothoracic Surgery jobs
Sun, 20 May 2012 16:37:38 -0500
All Cardiothoracic Surgery jobs for Sun May 20 2012
Cardiothoracic Surgery jobs in "Chief of Thoracic Oncology, Unparalleled Metro Location, #6353" - OK
Sun, 15 May 2011 12:15:44 -0600
Clinical prestige, ahead-of-the-curve technology and an unrivaled team environment await you at The University of Oklahoma Medical Center. This summer, we will open the doors on an impressive, new 210k-square-foot,
Cardiothoracic Surgery jobs in "Easy Access to both Cleveland and Pittsburgh" - PA
Sat, 19 May 2012 12:15:44 -0600
  This University community in Western PA is home to a well regarded four year liberal arts college which creates a very professional atmosphere in this community. The location is north of Pittsburgh

The Journal of Thoracic and Cardiovascular Surgery current issue

Quantitative assessment of right ventricular function in pectus excavatum [Online Only: Case Reports]
Narayan, R. L., Vaishnava, P., Castellano, J. M., Fuster, V. Mon, 14 May 2012 08:42:15 -0700

A new echocardiographic window to visualize the mitral valve complex during mitral valve repair for functional mitral regurgitation [Online Only: Case Reports]
Obase, K., Komeda, M., Okura, H., Yoshida, K. Mon, 14 May 2012 08:42:15 -0700

Historical perspectives of The American Association for Thoracic Surgery: Robert Edward Gross (1905-1988) [Presidential Perspectives]
Turek, J. W., Gaynor, J. W. Mon, 14 May 2012 08:42:14 -0700

Less invasive surgical treatment for aortic arch aneurysms in high-risk patients: A comparative study of hybrid thoracic endovascular aortic repair and conventional total arch replacement [Acquired Cardiovascular Disease]
Murashita, T., Matsuda, H., Domae, K., Iba, Y., Tanaka, H., Sasaki, H., Ogino, H. Mon, 14 May 2012 08:42:14 -0700
Objective For aortic arch aneurysms, conventional total arch replacement has been the standard surgical option. In selected high-risk patients, we have attempted less invasive hybrid procedure involving supra-aortic bypass and endovascular stent-graft placement. We review the early and midterm outcomes to clarify the impact of the hybrid procedure. Methods Between October 2007 and December 2010, 27 patients were treated with the hybrid procedure. During the same period, 191 patients underwent elective conventional total arch replacement. On retrospective analysis, the hybrid procedure was feasible in 103 patients (hybrid feasible) and not feasible in 88 patients (hybrid impossible). Patients undergoing the hybrid procedure attained significantly higher additive (11.6 ± 2.2 vs 9.5 ± 2.4, 10.3 ± 2.8, P < .001, P = .044) and logistic (31.1 ± 14.1 vs 18.8 ± 12.6, 23.7 ± 16.0, P < .001, P = .047) European System for Cardiac Operative Risk Evaluation scores than hybrid-feasible and hybrid-impossible groups. Results Although the patients in the hybrid group had significantly higher risk, the early outcomes including mortality and morbidity were similar among the 3 groups, as were the 2-year survivals during the follow-up period: 85.9% for the hybrid group, 89.6% for the hybrid-feasible group, and 86.7% for the hybrid-impossible group (P = .510, .850, log-rank test). In the hybrid group, 2 patients required reintervention for type I endoleak. Conclusions The early and midterm outcomes of the hybrid procedure for aortic arch aneurysms were satisfactory. This procedure has the potential to be an alternative for conventional total arch replacement for high-risk patients.
Simplified perfusion strategy for removing retroperitoneal tumors with extensive cavoatrial involvement [Acquired Cardiovascular Disease]
Navia, J. L., Brozzi, N. A., Nowicki, E. R., Blackstone, E. H., Krishnamurthi, V., Sinkewich, M. G., Rajeswaran, J., Pattakos, G., Lytle, B. W. Mon, 14 May 2012 08:42:14 -0700
Objectives Our objective was to compare effectiveness and safety of a simplified approach for removing retroperitoneal tumors with extensive cavoatrial involvement using beating-heart cardiopulmonary bypass (CPB) versus hypothermic circulatory arrest (HCA). Methods From January 1984 to January 2009, 144 patients underwent radical nephrectomy and inferior vena caval tumor thrombectomy, 56 (39%) using CPB and 88 (61%) HCA. Compared with HCA patients, CPB patients were of similar age (62 ± 10 vs 60 ± 11 years, P = .4) and gender (39% vs 39% female, P > .9), with similar stroke history (3.6% vs 2.3%, P =.6), but had less pulmonary disease (18% vs 33%, P = .06) and lower preoperative creatinine concentration (1.3 ± 0.72 vs 1.5 ± 0.86 mg · dL–1, P = .04). Results Complete tumor removal was achieved in all patients by both strategies. Compared with HCA procedures, CPB times were shorter (50 ± 33 vs 94 ± 40 minutes, P < .0001). CPB patients required fewer blood transfusions (36% no transfusion vs 17%, and 45% ≥4 units vs 72%; P = .003) and had no statistical difference in morbidity, including reoperation for bleeding (3.8% vs 8.0%, P = .3), renal failure requiring dialysis (3.6% vs 10%, P = .14), respiratory insufficiency (21% vs 19%, P = .8), sepsis (5.4% vs 10%, P = .3), stroke (5.4% vs 1.1%, P = .13), and in-hospital mortality (7.1% vs 13%, P = .3). Ten-year survival (22% vs 22%, P > .9) and freedom from cancer recurrence (24% vs 28%, P = .8) were similar. Conclusions Radical nephrectomy and removal of inferior vena caval tumor–thrombus can be simply, effectively, and safely performed with beating-heart CPB, avoiding the deleterious effects of HCA and providing clinical benefit without increasing morbidity or mortality.
A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial) [Acquired Cardiovascular Disease]
Bokesch, P. M., Szabo, G., Wojdyga, R., Grocott, H. P., Smith, P. K., Mazer, C. D., Vetticaden, S., Wheeler, A., Levy, J. H. Mon, 14 May 2012 08:42:14 -0700
Objective Ecallantide is a recombinant peptide in the same class as aprotinin that inhibits plasma kallikrein, a major component of the contact coagulation and inflammatory cascades. Therefore, ecallantide was expected to reduce blood loss associated with cardiac surgery requiring cardiopulmonary bypass. Methods This prospective multinational, randomized, double-blind trial enrolled patients undergoing cardiac surgery using cardiopulmonary bypass for procedures associated with a high risk of bleeding. Patients were randomly assigned to ecallantide (n = 109) or tranexamic acid (high dose, n = 24; low dose, n = 85). Efficacy was assessed from the volume of packed red blood cells administered within the first 12 hours after surgery. Results The study was terminated early after the independent data safety and monitoring board observed a statistically significantly higher 30-day mortality in the ecallantide group (12%) than in the tranexamic acid groups (4%, P = .041). Patients receiving ecallantide received more packed red blood cells within 12 hours of surgery than tranexamic acid-treated patients: median = 900 mL (95% confidence interval, 600–1070) versus 300 mL (95% confidence interval, 0–523) (P < .001). Similar differences were seen at 24 hours and at discharge. Patients treated with the higher tranexamic acid dose received less packed red blood cells, 0 mL (95% confidence interval, 280–600), than the group treated with the lower dose, 400 mL (95% confidence interval, 0–400) (P = .008). No deaths occurred in the higher dose tranexamic acid group. Conclusions Ecallantide was less effective at reducing perioperative blood loss than tranexamic acid. High-dose tranexamic acid was more effective than the low dose in reducing blood loss.

Subscribe to Cardiothoracic RSS feed